University of Pittsburgh logo
  1. Divisions
  2. Rheumatology
  3. Labs and Faculty Pages
  4. Torok Lab

Selected Publications

  1. Kurzinski K, Zigler CK and Torok KS (2018). Prediction of Disease Relapse in a Cohort of Juvenile Localized Scleroderma Patients.  Br J of Dermatol.  2018 Oct 13.  doi: 10.1111/bjd.17312. [Epub ahead of print] PMID: 30315656
  2. Mirizio E, Marathi A, Hershey N, Ross C, Schollaert K, Salgadgo CM, Reyes-Mugica M and Torok KS.  Identifying the signature immune phenotype present in pediatric Localized Scleroderma.  Journal of Investigative Dermatology.  Accepted September 24, 2018. 
  3. Li SC, Li X, Pope E, Stewart K, Higgins GC, Rabinovich CE, O'Neil KM, Haines KA, Laxer RM, Punaro M, Jacobe H, Andrews T, Wittkowski K, Nyirenda T, Foeldvari I, Torok KS. New Features for Measuring Disease Activity in Pediatric Localized Scleroderma. J Rheumatol. 2018 Sep 15. pii: jrheum.171381. dsoi: 10.3899/jrheum.171381. [Epub ahead of print] PubMed PMID: 30219769.
  4. Constantin T, Foeldvari I, Pain CE, Palinkas A, Höger P, Moll, M, Nemkova D, Weibel L, Laczkovski M, Clements P and Torok KS. Development of Minimum Standards of Care for Juvenile Localized Scleroderma. Eur J Pediatr (2018) 177: 961.  https://doi.org/10.1007/s00431-018-3144-8.  PMID: 29728839
  5. Foeldvari I, Klotsche J, Torok KS, Kasapcopur O, et. al. Are diffuse and limited juvenile systemic sclerosis different in clinical presentation?  Clinical characteristics of a juvenile systemic sclerosis cohort. J Scleroderma relat disorder; First Published August 7, 2018.  DOI: 10.1177/2397198318790494
  6. Stevens BS, Torok KS, Li SC, Hershey N, Curran M, Higgins GC, Moore KF, Rabinovich CE, Dodson S, Stevens A, and The CARRA Registry Investigators.  Clinical Characteristics and factors associated with disability and impaired quality of life in children with juvenile systemic sclerosis. Arthritis Care Res (Hoboken). 2018 Dec;70(12):1806-1813. doi: 10.1002/acr.23547. Epub 2018 Nov 8. PMID: 29457372
  7. Stevens AM, Kanaan SB, Torok KS, Medsger TA, et.al. HLA in Juvenile Systemic Sclerosis:  HLA DRB1. DQA1 and DQB1 in Juvenile Onset Systemic Sclerosis. Arthritis & Rheumatol; 2016 Nov; 68 (11): 2772-2777. DOI: 10.1002/art.39765 PMID: 27214100
  8. Ardalan K, Zigler CK, and Torok KS. Predictors of Longitudinal Quality of Life in Juvenile Localized Scleroderma. Arthritis Care Res (Hoboken) 2017; 69: 1082-1087.
  9. Kelsey CE and Torok KS. The Localized Scleroderma Cutaneous Assessment Tool: responsiveness to change in a pediatric clinical population. J Am Acad Dermatol 2013; 69: 214-220
  10. Kurzinski K and Torok KS. Cytokine profiles in localized scleroderma and relationship to clinical features. Cytokine 2011; 55: 157-164.
  11. Magee KE, Kelsey CE, Kurzinski KL, et al. Interferon-gamma inducible protein-10 as a potential biomarker in localized scleroderma. Arthritis research & therapy 2013; 15: R188.
  12. Poff S, Li SC, Kelsey CE, et al. Durometry as an outcome measure in juvenile localized scleroderma. Br J Dermatol 2016; 174: 228-230.
  13. Torok KS. Pediatric scleroderma: systemic or localized forms. Pediatric clinics of North America 2012; 59: 381-405.
  14. Torok KS and Arkachaisri T. Methotrexate and corticosteroids in the treatment of localized scleroderma: a standardized prospective longitudinal single-center study. J Rheumatol 2012; 39: 286-294
  15. Torok KS, Kurzinski K, Kelsey C, et al. Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles. Semin Arthritis Rheum 2015; 45: 284-293

Full Publication List via NIH PubMed »